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Prevalence and characteristics of
self-reported hypothyroidism and its
association with nonorgan-specific
manifestations in US sarcoidosis patients:
a nationwide registry study
Bashar N. Alzghoul 1, Farah N. Amer2, Diana Barb3, Ayoub Innabi1,
Mamoun T. Mardini 4,5, Chen Bai4, Bara Alzghoul6, Tamara Al-Hakim7,
Noopur Singh7, Mindy Buchanan7, Leslie Serchuck7, Diana Gomez Manjarres1,
Whitney W. Woodmansee3, Lisa A. Maier8,9 and Divya C. Patel 1
ABSTRACT Little is known about the prevalence, clinical characteristics and impact of hypothyroidism
in patients with sarcoidosis. We aimed to determine the prevalence and clinical features of hypothyroidism
and its relation to organ involvement and other clinical manifestations in patients with sarcoidosis.
We conducted a national registry-based study investigating 3835 respondents to the Sarcoidosis
Advanced Registry for Cures Questionnaire between June 2014 and August 2019. This registry is based on
a self-reported, web-based questionnaire that provides data related to demographics, diagnostics,
sarcoidosis manifestations and treatment. We compared sarcoidosis patients with and without self-
reported hypothyroidism. We used multivariable logistic regression and adjusted for potential confounders
to determine the association of hypothyroidism with nonorgan-specific manifestations.
14% of the sarcoidosis patients self-reported hypothyroidism and were generally middle-aged white
women. Hypothyroid patients had more comorbid conditions and were more likely to have multiorgan
sarcoidosis involvement, especially with cutaneous, ocular, joints, liver and lacrimal gland involvement.
Self-reported hypothyroidism was associated with depression (adjusted odds ratio (aOR) 1.3, 95% CI
1.01–1.6), antidepressant use (aOR 1.3, 95% CI 1.1–1.7), obesity (aOR 1.7, 95% CI 1.4–2.1), sleep apnoea
(aOR 1.7, 95% CI 1.3–2.2), chronic fatigue syndrome (aOR 1.5, 95% CI 1.2–2) and was borderline
associated with fibromyalgia (aOR 1.3, 95% CI 1–1.8). Physical impairment was more common in patients
with hypothyroidism.
Hypothyroidism is a frequent comorbidity in sarcoidosis patients that might be a potentially reversible
contributor to fatigue, depression and physical impairment in this population. We recommend considering
routine screening for hypothyroidism in sarcoidosis patients especially in those with multiorgan
sarcoidosis, fatigue and depression.
@ERSpublications
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sarcoidosis multiorgan involvement, and might be a potentially reversible contributor to fatigue,
depression and physical impairment in this population https://bit.ly/2XGdjKg
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Sarcoidosis can pose a devastating impact on healthcare-related quality of life (HRQoL) and can have
significant manifestations that appear to be nonorgan specific, such as fatigue and depression [1]. Due to
multiorgan involvement and the frequent comorbidities associated with sarcoidosis and its treatment, it
can be challenging to determine whether such manifestations are related to sarcoidosis or another
comorbid condition [2].
Autoimmune diseases are known to be associated with sarcoidosis; some have theorised that sarcoidosis
itself may be an autoimmune process [3, 4]. This link with autoimmune conditions perhaps explains the
association previously described between sarcoidosis and autoimmune thyroid disorders, albeit in small
studies or case series [5]. The exact prevalence and characteristics of hypothyroidism in sarcoidosis is
unknown [5–7]. A recent nationwide Taiwanese study found that 12% of sarcoidosis patients had an
autoimmune thyroid disorder [3].
Hypothyroidism has been linked to depression [8, 9], obesity [10], sleep apnoea [11], chronic fatigue [12]
and fibromyalgia [13] in the general population. Many patients with sarcoidosis suffer from these same
problems that are thought to be nonorgan specific. Interestingly, in a study evaluating idiopathic
pulmonary fibrosis patients, another type of interstitial lung disease, 17% had hypothyroidism and it was
found to be a predictor of mortality [14]. However, the contribution of hypothyroidism to the disease
manifestations, morbidity and mortality in sarcoidosis is unknown. Understanding the links between
hypothyroidism and sarcoidosis may lead to clearer understanding of the pathogenesis of sarcoidosis. It
may also help clinicians to understand the factors affecting HRQoL in sarcoidosis.
In this study, we sought to determine the prevalence of hypothyroidism in a self-reported nationwide
sarcoidosis registry from the United States. We also aimed to characterise the clinical features and cluster
of organ involvement in sarcoidosis patients who also have hypothyroidism and to study the possible




We conducted a national registry-based study investigating 3835 respondents to the Foundation for
Sarcoidosis Research (FSR) Sarcoidosis Advanced Registry for Cures Questionnaire (SARC) [15]. This
registry from FSR was open to all English-speaking patients self-identifying as having sarcoidosis via a
web-based questionnaire that includes 72 questions. Respondents were either directly recruited through
their treating physicians, by the FSR or via national and international organisations. It provides an
observational cohort platform to collect cross-sectional and longitudinal self-reported data related to
demographics, diagnostics, organ involvement, treatment and the physical and psychosocial impact of
sarcoidosis. We included patient surveys completed between June 2014 and August 2019. Respondents
were able to update their surveys longitudinally with time. Data from the most recent survey for each
respondent were used for our analysis. We excluded 13 patients who were reported to be deceased or had
missing information regarding the question “is the patient living” bringing the final cohort to a total of
3822 respondents. The study was approved by the University of Florida Institutional Review Board (no.
201902211).
Objectives and data management
The primary objective of the study was to define the prevalence of self-reported hypothyroidism in
patients with sarcoidosis. Secondary objectives were to determine the demographic and clinical
characteristics of the sarcoidosis patients who reported hypothyroidism; and to study the association of
hypothyroidism with the physical and nonorgan-specific manifestations of sarcoidosis. We divided the
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patients into two groups: those who self-reported hypothyroidism and those who did not report
hypothyroidism based on a response to a question in the survey regarding hypothyroidism (supplementary
table 1). We compared the following data between the two groups and reported it in three categories:
1) patient characteristics, diagnosis and treatment of sarcoidosis; 2) organ involvement and comorbidities
developed after the diagnosis of sarcoidosis; and 3) data regarding the physical impairment and
nonorgan-specific manifestations of the disease. The responses “unsure” or “prefer not to answer” were
labelled as missing information. Only complete cases were analysed for each variable. In each table, we
presented the nominator (positive cases) and denominator (complete cases) for each categorical variable.
Data missingness was <2% for demographics, <1% for insurance status, 19.8% for education, 22.7% for
income, 9.7% for hospitalisation history, <1% for steroid use history, 35.7% for cytotoxic agent use history,
47% for tumour necrosis factor (TNF) inhibitor use history and <2% for comorbid conditions. Missing
data regarding organ involvement ranged from 11% for lung involvement to 36.8% for bone involvement.
The question regarding endocrine and vitamin D disorders was a tick-box format so cases with empty
boxes were regarded as negative (supplementary table 1).
Patients reported comorbidities that have newly developed after the diagnosis of sarcoidosis. We divided
newly developed comorbidities into those probably related to sarcoidosis itself (cancer, chronic fatigue
syndrome, chronic pain syndrome, congestive heart failure, depression, fibromyalgia, lymphoma and sleep
disorders) and those probably related to the use of corticosteroids (diabetes mellitus, cataracts, glaucoma,
obesity, hypertension, osteoporosis/osteopenia and sleep apnoea) [16]. Multiorgan sarcoidosis was defined
by the reported presence of three or more organs affected by sarcoidosis [1, 17]. Systemic medications
used to treat sarcoidosis were divided into four categories: 1) steroids (prednisone, methylprednisolone,
dexamethasone); 2) cytotoxic agents (hydroxychloroquine, chloroquine, methotrexate, azathioprine,
leflunomide, mycophenolate, cyclophosphamide); 3) TNF inhibitors (infliximab, adalimumab,
certolizumab, golimumab, etanercept); and 4) other systemic therapies (rituximab, pentoxifylline,
intravenous Ig, thalidomide, adrenocorticotropic hormone).
We studied the association between self-reported hypothyroidism and the following comorbidities:
self-reported depression, chronic fatigue syndrome, fibromyalgia, sleep apnoea, sleep disorders and obesity.
We also looked at whether hypothyroidism was associated with patient reports of feeling depressed always
or often, using antidepressant medications and reporting feeling tired always or often. To investigate
physical impairment and social impact, questions regarding use of any mobility assistive device,
employment-based disability, missing more than seven work days in the past year and impact on job
termination were analysed (survey question details in supplementary table 1).
Validation cohort
To validate our results, we queried the University of Florida integrated data repository from January 2011
until September 2020 and identified patients who carry the diagnosis of sarcoidosis with and without
hypothyroidism and compared the presence and absence of depression, fatigue, fibromyalgia, obesity and
obstructive sleep apnoea based on International Classification of Diseases (ICD) codes. The following ICD
codes were used: sarcoidosis (ICD-9=135; ICD-10=D86); hypothyroidism (ICD-9=244; ICD-10=E03);
depression (ICD-9=311, 296.2 and 296.3; ICD-10=F32, F33); fatigue (ICD-9=780.7 and ICD-10=R53);
fibromyalgia (ICD-9=729.1 and ICD-10=M79.7); obesity (ICD-9=278, ICD-10=E65-E68) and obstructive
sleep apnoea ((OSA) ICD-9=327.23 and ICD-10=G47.33).
Data analysis
The distribution of patient characteristics and outcomes were summarised as percentages for categorical
variables and mean ±SD for continuous variables. To compare differences between groups, we used an
independent sample t-test for continuous variables and Chi-squared test for categorical variables. A
clustered bar chart was created to demonstrate the frequencies of other endocrine and vitamin D disorders
and different skin manifestations between groups. To study the association between self-reported
hypothyroidism and potential nonorgan-related and social manifestations in sarcoidosis patients,
multivariable logistic regression was performed adjusted for sex, race, age at diagnosis, use of steroids,
multiorgan involvement (as a binary variable) and whether the patient had other sarcoidosis-related
comorbidities (as a binary variable). These confounders were selected on an a priori basis. We also
adjusted for healthcare insurance status with the noted disparity between the two groups and its potential
impact on the outcomes. Based on this multivariable logistic regression analysis, we constructed a forest
plot to illustrate the odds ratio with 95% confidence intervals of the likelihood of nonorgan-related
manifestations in sarcoidosis patients with and without self-reported hypothyroidism. Statistical analyses
were performed using IBM SPSS Statistics for Windows, version 23.0 (released 2015, IBM Corp, Armonk,
NY, USA).
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Results
Demographics and baseline characteristics
Among the 3822 sarcoidosis patients identified for our analysis, 538 reported hypothyroidism with a prevalence
of 14.1%. The patients with self-reported hypothyroidism were generally middle-aged and were slightly older
than the nonhypothyroidism patients at the time of sarcoidosis diagnosis (45.1±12.5 versus 43.1±13.7 years,
p=0.001). The hypothyroidism patients were predominantly white women (table 1). Subgroup analysis showed
that the prevalence of hypothyroidism in all white females enrolled in the study was 20% (supplementary
table 2). Patients with hypothyroidism were more frequently seen by endocrinologists and other specialised
healthcare providers before the diagnosis of sarcoidosis was made. During the course of sarcoidosis, patients
with hypothyroidism received systemic corticosteroids more frequently as well as chloroquines, pentoxifylline
and intravenous Igs, when compared to patients without hypothyroidism. No significant difference was noted
in the use of TNF inhibitors or other cytotoxic agents (table 1 and supplementary figure 1).
Sarcoidosis organ involvement and comorbidities
Sarcoidosis patients with self-reported hypothyroidism also reported more multiorgan involvement (51%
versus 44%, p<0.001). Other self-reported endocrine and vitamin D disorders are presented in figure 1.
TABLE 1 Baseline demographics and clinical characteristics of sarcoidosis patients with
hypothyroidism as compared with patients with no hypothyroidism#
Hypothyroidism No hypothyroidism p-value
Demographics
Patients 538 3284
Age years¶ 45.1±12.5 43.1±13.7 0.001
Duration of disease years¶ 12.3±10.8 11.6±10.9 0.136
Women 486/538 (90) 2326/3284 (71) <0.001
Race
African American 41/530 (8) 667/3222 (21) <0.001
White 480/530 (91) 2521/3222 (78) <0.001
Other races+ 10/530 (2) 74/3222 (2) 0.55
Healthcare insurance
Private health insurance 332/531 (62.5) 1816/3256 (56) 0.004
Government insurance 211/531 (40) 1078/3256 (33) 0.003
No health insurance 55/531 (10) 621/3256 (19) <0.001
Graduated college or university 284/473 (60) 1394/2594 (54) 0.01
Income USD 0.50
<35000 127/442 (29) 656/2513 (26)
35000–99999 197/442 (44.5) 1173/2513 (47)
>100000 118/442 (26.5) 684/2513 (27)
Healthcare providers seen before sarcoidosis diagnosis was made§
Endocrinologist 115/538 (21) 241/3284 (7) <0.001
Primary care provider 436/538 (81) 2623/3284 (80) 0.53
Other specialists 451/538 (83) 2569/3284 (78) 0.003
Family history of sarcoidosis 81/446 (18) 476/2707 (18) 0.77
Ever admitted to hospital in relation to sarcoidosis 185/498 (37) 1158/2995 (39) 0.52
Sarcoidosis-specific therapyƒ
Steroids 416/536 (78) 2356/3262 (72) 0.009
Cytotoxic agents 254/382 (66.5) 1339/2076 (64.5) 0.45
Tumour necrosis factor inhibitors 79/312 (25) 376/1712 (22) 0.19
Others 38/291 (13) 142/1616 (9) 0.007
Data are presented as n, mean±SD or n/N total (%), unless otherwise stated. #: Missing values were
excluded for each variable. ¶: Age when the diagnosis of sarcoidosis was made or was extremely likely is
reported here. Duration is based on time difference in years between age at time of diagnosis and age at
time of survey answering. +: Other races include American Indian/Alaska Natives (127), Asian (32), Native
Hawaiian/Pacific Islander (9) and others (57). §: Primary care providers include family medicine doctors,
internists and/or general paediatricians. Other specialists include cardiologists, pulmonologists,
dermatologists, gastroenterologists, neurologists, ophthalmologists, psychiatrists and/or rheumatologists.
ƒ: Steroids: prednisone, methylprednisolone and dexamethasone. Cytotoxic agents: hydroxychloroquine,
chloroquine, methotrexate, azathioprine, leflunomide, mycophenolate and cyclophosphamide. Tumour
necrosis factor inhibitors: infliximab, adalimumab, certolizumab, golimumab and etanercept. Others:
rituximab, pentoxifylline, intravenous Ig, thalidomide, adrenocorticotropic hormone.
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These included disorders related to corticosteroid use and calcium metabolism. Furthermore, hypothyroid
patients had more skin, joint, eye, liver and lacrimal gland sarcoidosis-related manifestations (table 2).
Although there was no difference in the prevalence of pulmonary sarcoidosis, respondents with
self-reported hypothyroidism reported more use of home ventilators and noninvasive positive pressure
ventilation machines (31% versus 24%, p=0.001; data not shown). The cutaneous sarcoidosis
manifestations that were more common in the hypothyroid group included abnormal skin pigmentation,
erythema nodosum, lupus pernio, papules, plaques and s.c. nodules around scars and tattoos
(supplementary figure 2). Additionally, the hypothyroid group had more frequent comorbidities either
related to sarcoidosis disease or to steroids use (table 2).
Physical impairment and nonorgan-specific manifestations
On univariable analysis, when compared to patients with absence of hypothyroidism, patients with
self-reported hypothyroidism were more likely to report depression, obesity, sleep disorders, sleep apnoea,
chronic fatigue syndrome and fibromyalgia. They also reported using antidepressants, feeling depressed
most of the time and feeling tired most of the time more frequently when compared to patients without
hypothyroidism (table 3). Adjusting for baseline demographics and potential confounders including
corticosteroids use in multivariable logistic regression analysis, self-reported hypothyroidism was
associated with depression (adjusted odds ratio (aOR) 1.3, 95% CI 1.01–1.6), antidepressant use (aOR 1.3,
95% CI 1.1–1.7), obesity (aOR 1.7, 95% CI 1.4–2.1), sleep apnoea (aOR 1.7, 95% CI 1.3–2.2), chronic
fatigue syndrome (aOR 1.5, 95% CI 1.2–2) and was borderline associated with fibromyalgia (aOR 1.3, 95%
CI 1–1.8) (table 3 and figure 2). Furthermore, hypothyroidism was associated with employment-based
disability, missing work days and disease-related job termination in univariable analysis but only with
missing work days when adjusting for potential confounders (table 3).
Validation cohort results
Using the University of Florida database, we identified 2189 adult sarcoidosis patients, of which 1324
(60.5%) were female, 834 (38%) were African American and 328 (15%) also carried the diagnosis of
hypothyroidism. Hypothyroidism patients were mainly female (75%) and white (65%). Compared to
Subjects %
Nonhypothyroidism Hypothyroidism




















0 10 20 30 40 50 60
FIGURE 1 Clustered bar chart demonstrating the frequencies of other endocrine and vitamin D disorders in sarcoidosis patients with
hypothyroidism as compared with those with no hypothyroidism.
https://doi.org/10.1183/23120541.00754-2020 5
INTERSTITIAL LUNG DISEASE | B.N. ALZGHOUL ET AL.
sarcoidosis patients without hypothyroidism, hypothyroidism patients significantly had more
depression (OR 2.6, 95% CI 2–3.4), fatigue (OR 2.1, 95% CI 1.7–2.7), fibromyalgia (OR 2.8, 95% CI
2–3.9), obesity (OR 1.7, 95% CI 1.3–2.2) and OSA (OR 1.9, 95% CI 1.4–2.4) (supplementary table 3).
Discussion
To our knowledge, this is the largest study in the published literature to assess the prevalence,
characteristics and potential impact of hypothyroidism in sarcoidosis patients [3, 6, 7, 18–24]. Our study
shows that 14% of sarcoidosis patients reported hypothyroidism. These patients were mainly middle-aged
white females. Hypothyroidism was more likely to be reported in sarcoidosis with multiorgan involvement,
especially when involving the skin, joints, eyes, liver and/or the lacrimal glands. Furthermore, self-reported
hypothyroidism was associated with depression, fatigue, obesity, sleep apnoea and physical impairment.
In this nationwide sarcoidosis cohort, the reported prevalence of self-reported hypothyroidism is
remarkably higher than what is reported in the general population, which ranges between 3% and 7% in
the United States [12]. Notably, sarcoidosis patients with hypothyroidism had a similar demographic
profile as the general population of hypothyroidism patients [12]. Our prevalence is similar to what has
been observed in other smaller sarcoidosis cohorts. ANTONELLI et al. [6] reported 17% prevalence of
subclinical hypothyroidism and 5% prevalence of overt hypothyroidism in sarcoidosis patients from Italy.
MALLI et al. [7] reported a 15% prevalence in a cohort from Greece. In a nationwide case–control study
from Taiwan looking at sarcoidosis comorbid conditions, the prevalence of autoimmune thyroid disease
was around 12% [3].
Our study does not answer the question of whether hypothyroidism is caused by autoimmune thyroiditis,
direct sarcoidosis infiltration of the thyroid gland, other causes or is multifactorial. Although direct
evidence of autoimmunity as the cause of sarcoidosis is lacking, associations with autoimmune conditions,
TABLE 2 Sarcoidosis involvement of other organs as reported by sarcoidosis patients with
hypothyroidism as compared to those with no hypothyroidism#
Hypothyroidism No hypothyroidism p-value
Patients 538 3284
Multiorgan sarcoidosis ⩾3 organs¶ 276/532 (52) 1444/3154 (46) 0.009
Lungs 377/492 (77) 2201/2909 (76) 0.64
Bones or vertebrae 43/352 (12) 234/2062 (11) 0.64
Brain or cranial nerves 51/351 (14.5) 275/2077 (13) 0.51
Peripheral nerves 105/387 (27) 518/2234 (23) 0.09
Central lymph nodes+ 282/431 (65) 1431/2457 (58) 0.005
Peripheral lymph nodes§ 122/391 (31) 623/2210 (28) 0.23
Eyes 138/405 (34) 604/2318 (26) 0.001
Cardiac 59/384 (15) 335/2196 (15) 0.96
Joints 141/408 (35) 632/2314 (27) 0.003
Kidneys 33/350 (9) 163/2047 (8) 0.36
Parotid or lacrimal glands 35/351 (10) 130/1985 (6.5) 0.02
Stomach/intestines 34/360 (9) 153/2080 (7) 0.17
Liver 72/367 (20) 312/2125 (15) 0.02
Spleen 51/356 (14) 287/2064 (14) 0.83
Muscles 39/355 (11) 209/2079 (10) 0.59
Sinuses 45/363 (12) 216/2149 (10) 0.18
Skin 167/412 (40.5) 750/2308 (32.5) 0.001
Newly arising comorbidities after sarcoid diagnosisƒ
Probably sarcoid-related 274/498 (55) 1352/3284 (41) <0.001
Probably steroid-related 284/498 (57) 1377/3284 (42) <0.001
Data are presented as n or n/N total (%), unless otherwise stated. #: Patients were asked whether or not
the organ involvement is a confirmed diagnosis, suspected or if they were unsure. Prevalence presented in
this table is based on confirmed diagnosis only as reported by the patients. For this analysis, answers
suspected or “not involved” were regarded as “not involved”. “Unsure” or missing were regarded as
missing values. ¶: Multiorgan sarcoidosis defined if three or more organs were involved. +: Lymph nodes
in the chest and abdomen. §: Axillary, cervical and inguinal lymph nodes. ƒ: Probably sarcoid-related:
cancer, chronic fatigue syndrome, chronic pain syndrome, congestive heart failure, depression,
fibromyalgia, lymphoma and sleep disorders; probably steroid-related: diabetes mellitus, cataracts,
glaucoma, obesity, hypertension, osteoporosis/osteopenia and sleep apnoea.
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TABLE 3 Physical impairment and psychosocial impact of hypothyroidism in patients with sarcoidosis
Hypothyroidism No hypothyroidism Adjusted odds ratio (95% CI)#
Patients n 538 3284
Psychosomatic impact
Depression¶ 141/489 (29) 748/3284 (23) 1.3 (1.01–1.6)
Feeling depressed+ 167/504 (33) 794/2781 (29) 1.1 (0.9–1.4)
Use of antidepressants§ 204/530 (39) 872/3210 (27) 1.3 (1.1–1.7)
Obesity 125/489 (26) 544/3284 (17) 1.7 (1.4–2.1)
Sleep apnoea 132/489 (27) 559/3077 (18) 1.7 (1.3–2.2)
Chronic fatigue syndrome 138/491 (28) 590/3284 (18) 1.5 (1.2–2)
Feeling tired+ 434/508 (85) 2218/2801 (79) 1.1 (0.8–1.5)
Fibromyalgia 89/484 (18) 325/3284 (10) 1.3 (0.97–1.8)
Physical impairment and social impact
Use of mobility assistive devicesƒ 99/538 (18) 478/3277 (15) 1.1 (0.8–1.4)
Employment-based disability 164/514 (32) 747/3207 (23) 1.2 (0.95–1.5)
Missing more than 7 work days in the past year 155/280 (55) 796/1749 (46) 1.2 (1.02–1.6)
Job termination due to illness 159/391 (41) 791/2321 (34) 1.1 (0.9–1.4)
Data are presented as n or n/N total (%), unless otherwise stated. #: Multivariable logistic regression analysis adjusted for sex, race, age at
diagnosis, healthcare insurance status, use of steroids, multiorgan involvement and other sarcoidosis-related comorbidities (cancer, chronic
pain syndrome, congestive heart failure and lymphoma). The effective sample size that was kept in the adjusted complete-case analyses was
92% for depression, 81% for “feeling depressed”, 90% for antidepressants use, 92% for obesity, 87% for sleep apnoea, 92% for chronic fatigue
syndrome, 82% for “feeling tired”, 92% for fibromyalgia, 92% for “use of mobility device”, 90% for disability, 51% for work days missing and
67% for job termination. ¶: Depression disorder developed after the diagnosis of sarcoidosis as reported by respondents. +: Feeling depressed
or feeling tired defined if patient answered feeling tired/depressed often or always. §: Antidepressants reported include citalopram (Celexa),
fluoxetine (Prozac), escitalopram (Lexapro), fluvoxamine (Luvox), duloxetine (Cymbalta), venlafaxine (Effexor), paroxetine (Paxil) and sertraline
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FIGURE 2 Forest plot showing the adjusted odds ratio of the likelihood of different nonorgan-specific
conditions in patients with sarcoidosis who also have hypothyroidism versus those with no hypothyroidism.
Odds ratio with confidence intervals are based on multivariable logistic regression analysis adjusted for sex,
race, age at diagnosis, healthcare insurance status, use of steroids, multiorgan involvement and other
sarcoidosis-related comorbidities (cancer, chronic pain syndrome, congestive heart failure and lymphoma).
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including thyroid disease, have been noted [3, 4, 24]. Enhanced T-cell immunity along with loss of T-cell
tolerance to self-antigens and possible exogenous antigenic exposure have all been proposed to play a role
in the pathophysiology of sarcoidosis [4, 25]. Additionally, the increase in circulating Igs and the possible
response to B-cell-depleting therapy in refractory cases might also suggest a role of the humoral immune
system [26]. Recently, sarcoidosis patients were found to have elevated levels of age-associated B-cells in
their blood and bronchoalveolar lavage as compared to healthy subjects, supporting the role of B-cell
immunity [27]. This autoimmune phenomenon in sarcoidosis might explain the higher prevalence of
hypothyroidism noted in our sarcoidosis cohort as compared to the general population. Previous studies
have also shown that sarcoidosis patients have higher levels of thyroid peroxidase antibodies [19] and/or
thyroglobulin antibodies [19, 20] when compared to control subjects, which might have a
pathophysiological role in the association between sarcoidosis and autoimmune thyroid disease [5].
Another possible mechanism of hypothyroidism in sarcoidosis is direct granulomatous thyroid infiltration,
which is reported in around 4% in autopsy studies of systemic sarcoidosis patients [5, 28]. Various
treatments for sarcoidosis, including systemic use of steroids or other immunosuppression treatments, can
alter thyroid function tests [29]. High doses of systemic steroids can reduce thyroid-stimulating hormone
levels but this effect is usually transient and reversible and not typically associated with clinical central
hypothyroidism [29]. Other immune suppressing agents such as cyclophosphamide [30], infliximab [31]
and chloroquine [32] have been reported to cause hypothyroidism. In our analysis, patients with
self-reported hypothyroidism were more likely to have received corticosteroids, chloroquines, pentoxifylline
and intravenous Ig when compared to sarcoidosis patients without hypothyroidism, which might suggest a
potential contribution from medications in hypothyroidism, and or to treat associated organ involvement.
A novel finding in our study is the link that we noted between self-reported hypothyroidism and
multiorgan involvement of sarcoidosis. It is unclear from our analysis whether the same mechanism
underlying the development of multiorgan sarcoidosis also underlies the development of hypothyroidism;
autoimmunity has been postulated as a mechanism for development of nonpulmonary disease although an
exuberant antigen-driven immune response is often noted in multiorgan disease [33]. Other than the
lungs and lymphatic system, the most common organ systems reported to be involved with sarcoidosis in
the self-reported hypothyroid group were the skin, joints and eyes. The association with cutaneous
sarcoidosis was previously reported by ANOLIK et al. [22] who linked the development of thyroid disorders
with cutaneous sarcoidosis, although the underlying mechanisms of this association are not clear.
Nonorgan-specific symptoms and social and physical impairment related to sarcoidosis can have a large
burden on the patients’ HRQoL. Sarcoidosis-associated fatigue is a challenging problem that is common in
sarcoidosis [2]. It is likely multifactorial in origin and often very difficult to treat [2]. Several studies
evaluated pharmacological and nonpharmacological approaches to treat fatigue in sarcoidosis; however,
none of these studies looked at hypothyroidism and fatigue in this patient population [34–39]. In one
study of German patients evaluating excessive daytime sleepiness and fatigue predictors in sarcoidosis,
BOSSE-HENCK et al. [40] found an increased prevalence of “thyroid disorders” in patients with fatigue and
excessive daytime sleepiness. Interestingly, in a recently published article phenotyping sarcoidosis organ
involvement, fatigue was linked to female sex in sarcoidosis and to cardiac, central nervous system and
skin sarcoidosis involvement. However, hypothyroidism was not included in that model [41]. In our
analysis, sarcoidosis patients with hypothyroidism were 1.5-times more likely to report fatigue when
compared to sarcoidosis patients without hypothyroidism. Chronic fatigue was previously reported to be
associated with other comorbidities, including depression, obesity, sleep apnoea and fibromyalgia [2, 40].
We found an association between self-reported hypothyroidism and all four conditions even after
controlling for corticosteroid use, suggesting that fatigue in sarcoidosis is multifactorial and may also be
linked to hypothyroidism.
We acknowledge several limitations. Despite the extensive recruitment efforts and the relatively large
sample size, the participation is still limited by access, awareness and ability to take an online survey. It is
clear that the data disproportionately represented white patients (80%) and women (73.6%), which limits
the generalizability of our results. However, our reported prevalence of hypothyroidism is in the range
with what has been reported in other smaller but more defined sarcoidosis cohorts. Furthermore, using
the University of Florida database of sarcoidosis patients, including 40% men and 38% African American
people, the prevalence of hypothyroidism was 15%, which was also associated with depression, fatigue,
fibromyalgia, obesity and obstructive sleep apnoea, suggesting that our results may have generalizability
despite these limitations. Another limitation is the recruitment process, given the platform in which the
survey is administered, which leads to referral bias. Furthermore, patients who chose to participate in the
survey may not necessarily represent the general sarcoidosis population as those with more severe disease
were likely over-represented. Also, the self-reported nature of the data opens the door for nondifferential
misclassification of exposure and outcomes. This may explain the higher rates of extrathoracic sarcoidosis
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in almost all organ systems when compared to published literature. Unfortunately, self-reported registry
studies are commonly subject to this bias; however, the large participant number, statistical adjustment for
demographics and potential confounders and the external validation that we performed may address this
limitation to some degree. Finally, we cannot establish a causality relationship between hypothyroidism
and the tested outcomes due to the self-reported observational nature of this study. However, our study
highlights the importance of considering hypothyroidism as a potentially treatable factor among other
factors contributing to the physical and nonorgan-related disability in sarcoidosis.
Conclusion
In conclusion, self-reported hypothyroidism is prevalent in sarcoidosis and may be an important
potentially treatable contributor of disabling symptoms. It is often associated with multiorgan involvement.
Based on our findings, routine screening for hypothyroidism should be considered in sarcoidosis patients,
especially in those with multiorgan involvement, fatigue and depression. Further investigation is needed to
determine common pathogenic pathways and to assess the impact of treatment of hypothyroidism has on
the nonorgan-specific symptoms in sarcoidosis.
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